ANALYSIS OF VARIATIONS OF LP(A) LEVELS AS A BIOMARKER OF CARDIOVASCULAR DISEASES IN VARIOUS POPULATIONS

ANALYSIS OF VARIATIONS OF LP(A) LEVELS AS A BIOMARKER OF CARDIOVASCULAR DISEASES IN VARIOUS POPULATIONS

Elevated lipoprotein(a) plasma concentration - [Lp(a)] is considered a risk factor for cardiovascular disease (CVD). In African Americans (AA) have 2-3 times above [Lp(a)] than in Europeans and Asians, for example, in Chinese - 7.0 mg/dl, in black Sudanese - 46 mg/dl. Some authors believe that the a...

Full description

Bibliographic Details
Main Authors:	I. N. Grigorieva, Yu. I. Ragino, T. I. Romanova
Format:	Article
Language:	Russian
Published:	Siberian Branch of Russian Academy of Sciences, Research Institute of Internal and Preventive Medicine, branch of the Institute of Cytology and Genetics 2018-03-01
Series:	Атеросклероз
Subjects:	lipoprotein(a) apolipoprotein(a) cardiovascular risk african-americans europeans asians aboriginals of chukotka
Online Access:	https://ateroskleroz.elpub.ru/jour/article/view/66/66

Similar Items

The kringle IV type 2 domain variant 4925G>A causes the elusive association signal of the LPA pentanucleotide repeat
by: Rebecca Grüneis, et al.
Published: (2022-12-01)

Hypertensive Disorders of Pregnancy: Assessing the Significance of Lp(a) and ApoB Concentrations in a Romanian Cohort
by: Simona-Alina Abu-Awwad, et al.
Published: (2023-09-01)

Hypertriglyceridemia promotes dysfunctions in high-density lipoprotein increasing the cardiovascular risk
by: Richard Rarison Cavalcante Meneses, et al.
Published: (2023-01-01)

Current Management and Future Perspectives in the Treatment of Lp(a) with a Focus on the Prevention of Cardiovascular Diseases
by: Juan M. Farina, et al.
Published: (2023-06-01)

Elevated Lp(a) Levels Correlate with Severe and Multiple Coronary Artery Stenotic Lesions
by: Al Hageh C, et al.
Published: (2023-01-01)

Association of apolipoproteins and lipoprotein(a) with metabolic syndrome: a systematic review and meta-analysis
by: Juan R. Ulloque-Badaracco, et al.
Published: (2023-07-01)

Developing Electron Microscopy Tools for Profiling Plasma Lipoproteins Using Methyl Cellulose Embedment, Machine Learning and Immunodetection of Apolipoprotein B and Apolipoprotein(a)
by: Yvonne Giesecke, et al.
Published: (2020-09-01)

Effect of the Fat Eaten at Breakfast on Lipid Metabolism: A Crossover Trial in Women with Cardiovascular Risk
by: Jessica M. Delgado-Alarcón, et al.
Published: (2020-06-01)

Consensus document for lipid profile testing and reporting in Spanish clinical laboratories: what parameters should a basic lipid profile include?
by: Arrobas Velilla Teresa, et al.
Published: (2023-06-01)

Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases
by: Victoria A. Korneva, et al.
Published: (2021-09-01)

Lipoproteins as Drug Carriers for Cyclosporine A: Optimization of the Entrapment
by: Mona M. A. Abdel-Mottaleb, et al.
Published: (2023-01-01)

Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
by: Chih-Kuo Lee, et al.
Published: (2021-08-01)

Lipid Profile, Lp(a) Levels, and HDL Quality in Adolescents with Down Syndrome
by: Aleksandra Krzesińska, et al.
Published: (2022-07-01)

Lipoprotein(a) induces caspase-1 activation and IL-1 signaling in human macrophages
by: Martina B. Lorey, et al.
Published: (2023-05-01)

Lipoprotein(a) Serum Levels Predict Pulse Wave Velocity in Subjects in Primary Prevention for Cardiovascular Disease with Large Apo(a) Isoforms: Data from the Brisighella Heart Study
by: Arrigo F. G. Cicero, et al.
Published: (2022-03-01)

Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
by: Eftaxia-Konstantina Valanti, et al.
Published: (2018-10-01)

SERUM LIPOPROTEIN(a) LEVEL IN SUBJECTS FREE OF CLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS-RELATED DISEASES: THE RELATIONSHIP WITH LIPID AND GLUCOSE METABOLISM PARAMETERS AND ARTERIAL STIFFNESS
by: O. V. Alexandrovich, et al.
Published: (2019-06-01)

2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk
by: Francois Mach, et al.
Published: (2020-06-01)

Lp(a) and inflammation: a new insight into atherosclerosis
by: Hangyu Pan, et al.
Published: (2023-10-01)

Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis
by: Paulina Kiluk, et al.
Published: (2020-07-01)

Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease
by: Lijun Zhu, et al.
Published: (2022-11-01)

Hyperlipoproteinemia(a) as a dangerous genetically determined violation of lipid metabolism and a risk factor for atherothrombosis and cardiovascular diseases
by: O. I. Afanasieva, et al.
Published: (2019-06-01)

Association of Acculturation with Cardiovascular Risk Factors in Asian-American Subgroups
by: Yuemeng LI, et al.
Published: (2023-03-01)

Lipoprotein(a)—60 Years Later—What Do We Know?
by: Anna Pasławska, et al.
Published: (2023-10-01)

The effect of 17β-estradiol plus norethisterone acetate treatment on lipoprotein (a), atherogenic and anti-atherogenic apolipoproteins levels in postmenopausal women: A meta-analysis of randomized controlled trials
by: Zengyao Tang, et al.
Published: (2023-02-01)

Enhancement of High-Density Lipoprotein (HDL) Quantity and Quality by Regular and Habitual Exercise in Middle-Aged Women with Improvements in Lipid and Apolipoprotein Profiles: Larger Particle Size and Higher Antioxidant Ability of HDL
by: Kyung-Hyun Cho, et al.
Published: (2023-01-01)

Long-Term Alcohol Consumption Caused a Significant Decrease in Serum High-Density Lipoprotein (HDL)-Cholesterol and Apolipoprotein A-I with the Atherogenic Changes of HDL in Middle-Aged Korean Women
by: Kyung-Hyun Cho, et al.
Published: (2022-08-01)

Lipoprotein a - Lp(a)
by: Tapan Ghose
Published: (2024-03-01)

A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease
by: Alankrita Rani, et al.
Published: (2023-05-01)

Assessment of Apolipoprotein(a) Isoform Size Using Phenotypic and Genotypic Methods
by: Federica Fogacci, et al.
Published: (2023-09-01)

Association of acute Babesia canis infection and serum lipid, lipoprotein, and apoprotein concentrations in dogs
by: Zorana Milanović, et al.
Published: (2019-07-01)

Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease
by: Narek A. Tmoyan, et al.
Published: (2021-01-01)

Reducing saturated fat intake lowers LDL-C but increases Lp(a) levels in African Americans: the GET-READI feeding trial
by: Hayley G. Law, et al.
Published: (2023-09-01)

Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option
by: Alessandro Maloberti, et al.
Published: (2022-12-01)

Combination Therapy of Cuban Policosanol (Raydel<sup>®</sup>, 20 mg) and Intensive Exercise for 12 Weeks Resulted in Improvements in Obesity, Hypertension, and Dyslipidemia without a Decrease in Serum Coenzyme Q<sub>10</sub>: Enhancement of Lipoproteins Quality and Antioxidant Functionality in Obese Participants
by: Kyung-Hyun Cho, et al.
Published: (2024-01-01)

Evidence and Uncertainties on Lipoprotein(a) as a Marker of Cardiovascular Health Risk in Children and Adolescents
by: Simonetta Genovesi, et al.
Published: (2023-06-01)

Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities
by: Zlatko Fras
Published: (2020-01-01)

Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus
by: Karam M. Kostner, et al.
Published: (2022-03-01)

Social Determinants of Cardiovascular Risk Factors Among Asian American Subgroups
by: Alicia L. Zhu, et al.
Published: (2024-04-01)

Elevated Lipoprotein (a) and 10-Year Risk of Cardiovascular Disease among Iranian Patients with Bipolar Disorder
by: Shadi Naderyan feli, et al.
Published: (2021-05-01)